SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to US FDA approval for generic Mesalamine Extended Release Capsules.12-05-2022
12-05-2022
What is USFDA's Form 483?
The US carries out regular inspections at offshore drug making units to ensure quality compliance. In a recent check, the US FDA has issued Form 483 to Sun Pharma Halol unit. Let's demystify Form 48312-05-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 11, 2022 for Raksha Sudhir Valia11-05-2022
Halol troubles continue for Sun Pharma
Limited impact on growth as only 3-4 per cent of consolidated sales is sourced from Halol10-05-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company SUN PHARMACEUTICAL INDUSTRIES LTD. 2 CIN NO. L24230GJ1993PLC019050 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2021-22, FY 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0.00 8Quantum of (d), which has been met from (c)(e)* 0.00 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0.00 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2020-21, FY 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Anoop DeshpandeDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- C S Muralidharan Designation : -Chief Financial Officer Date: 09/05/202209-05-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2022 for Raksha Sudhir Valia29-04-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 27, 2022 for Shanghvi Finance Pvt Ltd27-04-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201527-04-2022
Aurobindo, Sun Pharma, Jubilant recall products in US market: USFDA
Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons24-04-2022